Clinical research

ATTAIN-1: Orforglipron for chronic weight management

Phase 3, randomised, double-blind, placebo-controlled. Over 1,600 randomised, over 72 weeks. Sponsor: Eli Lilly and Company.

ATTAIN-1 (no registry ID on file) tested orforglipron, once-daily oral non-peptide glp-1 receptor agonist at Up to 17.2 mg once daily against placebo in adults with obesity, or overweight with weight-related comorbidities. over 1,600 randomised across the us, argentina, australia, brazil, china, czechia, germany, greece, india, south korea and puerto rico.Approximately 11% to 12.4% mean weight reduction at the highest dose over 72 weeks. Lilly states 12.4% at the highest dose; secondary coverage cites approximately 11% Unverified — no source on file: the source is a citable record we could not authoritatively link, which we have not independently re-extracted from the full paper in this session.

Study design

Results

Approximately 11% to 12.4% mean weight reduction at the highest dose over 72 weeks. Lilly states 12.4% at the highest dose; secondary coverage cites approximately 11%

Adverse events & discontinuations

Predominantly gastrointestinal — nausea, vomiting, diarrhoea, constipation, abdominal pain. Boxed warning for thyroid C-cell tumours including medullary thyroid carcinoma

Limitations

Industry-funded. The published figure varies between sources (11% to 12.4%) depending on the analysis quoted; the estimand behind each is not consistently stated. Substantially lower mean reduction than injectable tirzepatide or either semaglutide formulation, which matters when the drug is compared on price alone.

Practical interpretation

This is one trial, reported by Eli Lilly and Company, read directly against the registry and publication linked below — GLP Ranked has not re-run the statistics or obtained the patient-level data. Results describe group averages under trial conditions and may not describe any individual's outcome, including with a compounded, non-FDA-approved version of a similar active ingredient. Always check the primary source before citing a specific number.